Valneva SE (VALN) Other financing activities (2021 - 2022)

Valneva SE (VALN) posted Other financing activities of -$54073.1 for Q4 2022, down 101.85% sequentially from $2.9 million in Q3 2022, and down 4826.79% YoY from $1144.0 in Q4 2021.

Valneva SE (VALN) Other financing activities (2021 - 2022) Analysis & Trends

Valneva SE has reported Other financing activities for 2 years, with the latest figure at -$54073.1 in Q4 2022.

  • Quarterly Other financing activities fell 4826.79% year-over-year to -$54073.1 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$54073.1 (down 101.81% YoY) and the FY2022 annual result came in at $3.1 million, up 5765.94% from the prior year.
  • Other financing activities retreated to -$54073.1 in Q4 2022 per VALN's latest filing, from $2.9 million in the prior quarter.
  • Over five years, Other financing activities peaked at $2.9 million in Q3 2022 and troughed at -$54073.1 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Valneva SE 618.67 Mn 477.41 Mn 1.86 Mn

Historic Data

Download Data
DateValue
Dec 31, 2022 -54,073.11
Dec 31, 2022 -54,073.11
Sep 30, 2022 2.93 Mn
Sep 30, 2022 2.93 Mn
Jun 30, 2022 3,201.17
Jun 30, 2022 3,201.17
Mar 31, 2022 50,505.20
Mar 31, 2022 50,505.20
Dec 31, 2021 1,143.97
Dec 31, 2021 1,143.97
Sep 30, 2021 1,179.29
Sep 30, 2021 1,179.29
Jun 30, 2021 -1,204.27
Jun 30, 2021 -1,204.27
Mar 31, 2021 51,868.15
Mar 31, 2021 51,868.15